| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10007053 | HBV | ENSG00000128052.10 | protein_coding | KDR | Yes | No | 3791 | P35968 |
| TVIS10007054 | HBV | ENSG00000128052.10 | protein_coding | KDR | Yes | No | 3791 | P35968 |
| TVIS10016656 | HBV | ENSG00000128052.10 | protein_coding | KDR | Yes | No | 3791 | P35968 |
| TVIS10000123 | HBV | ENSG00000128052.10 | protein_coding | KDR | Yes | No | 3791 | P35968 |
| TVIS20058066 | HPV | ENSG00000128052.10 | protein_coding | KDR | Yes | No | 3791 | P35968 |
| TVIS44025335 | HTLV-1 | ENSG00000128052.10 | protein_coding | KDR | Yes | No | 3791 | P35968 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | KDR |
|---|---|
| DrugBank ID | DB01268 |
| Drug Name | Sunitinib |
| Target ID | BE0000369 |
| UniProt ID | P35968 |
| Regulation Type | inhibitor |
| PubMed IDs | 12538485; 12873999; 14753710; 16418310; 16533791; 11752352 |
| Citations | Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003 Jan;9(1):327-37.@@Schueneman AJ, Himmelfarb E, Geng L, Tan J, Donnelly E, Mendel D, McMahon G, Hallahan DE: SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res. 2003 Jul 15;63(14):4009-16.@@Baratte S, Sarati S, Frigerio E, James CA, Ye C, Zhang Q: Quantitation of SU1 1248, an oral multi-target tyrosine kinase inhibitor, and its metabolite in monkey tissues by liquid chromatograph with tandem mass spectrometry following semi-automated liquid-liquid extraction. J Chromatogr A. 2004 Jan 23;1024(1-2):87-94.@@Schoffski P, Dumez H, Clement P, Hoeben A, Prenen H, Wolter P, Joniau S, Roskams T, Van Poppel H: Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review. Ann Oncol. 2006 Aug;17(8):1185-96. Epub 2006 Jan 17.@@Amino N, Ideyama Y, Yamano M, Kuromitsu S, Tajinda K, Samizu K, Hisamichi H, Matsuhisa A, Shirasuna K, Kudoh M, Shibasaki M: YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors. Clin Cancer Res. 2006 Mar 1;12(5):1630-8.@@Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. |
| Groups | Approved; Investigational |
| Direct Classification | Indolines |
| SMILES | CCN(CC)CCNC(=O)C1=C(C)NC(C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C |
| Pathways | |
| PharmGKB | PA162372840 |
| ChEMBL | CHEMBL535 |
